search
Back to results

Safety and Efficacy of SA09012 in Asthma

Primary Purpose

Mild to Moderate Bronchial Asthma

Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
SA09012 Low dose
SA09012 High dose
Placebo
Sponsored by
SamA Pharmaceutical Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mild to Moderate Bronchial Asthma focused on measuring Asthma

Eligibility Criteria

20 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis or presence of asthma within 3 months of the prestudy visit

    1. Increase in PEF ≥ 20% or ≥ 60L/min from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit
    2. Increase in FEV1 ≥ 12% and ≥ 200mL from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit
  • FEV1 or PEF between 60% and 85% of the predicted value at screening or within the 3 months of the prestudy visit
  • Having signed an informed consent

Exclusion Criteria:

  • Patient who has severe asthma
  • Patient who has any significant medical condition that might compromise patient safety, interfere with evaluation or preclude completion of the study other protocol-defined inclusion/exclusion criteria may apply
  • Patient with an AST or ALT > 2x ULN (upper limit of normal) in the screening visit
  • Patient with more than 10 pack year of cigarettes history

Sites / Locations

  • Chonbuk National University Hospital
  • Chungbuk National University Hospital
  • Chonnam National University Hospital
  • Ajou University Hospital
  • Bucheon St. Mary's Hospital, The Catholic University of Korea
  • Hallym University Sacred Heart Hospital
  • Soon Chun Hyang University Bucheon Hospital
  • Konkuk University Medical Center
  • Korea University Guro Hospital
  • KyungHee University Medical Center
  • Seoul St. Mary's Hospital, The Catholic University of Korea
  • Soonchunhyang University Hospital, Seoul
  • St. Paul's Hospital, The Catholic University of Korea
  • Yonsei University, Gangnam Severance Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

SA09012 Low dose

SA09012 High dose

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Mean change from baseline of PEF(Peak Expiratory Flow)at week 6

Secondary Outcome Measures

Mean change from baseline in FEV1 at week 6
Mean change from baseline in ACT(Asthma Control Test) at week 6
Safety assessment(Comparison of the adverse event profiles throughout the course of the study)

Full Information

First Posted
November 30, 2012
Last Updated
November 13, 2015
Sponsor
SamA Pharmaceutical Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT01740986
Brief Title
Safety and Efficacy of SA09012 in Asthma
Official Title
Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
November 2012 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
November 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SamA Pharmaceutical Co., Ltd

4. Oversight

5. Study Description

Brief Summary
Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild to Moderate Bronchial Asthma
Keywords
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
225 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SA09012 Low dose
Arm Type
Experimental
Arm Title
SA09012 High dose
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
SA09012 Low dose
Intervention Description
Tablet, b.i.d
Intervention Type
Drug
Intervention Name(s)
SA09012 High dose
Intervention Description
Tablet, b.i.d
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Tablet, b.i.d
Primary Outcome Measure Information:
Title
Mean change from baseline of PEF(Peak Expiratory Flow)at week 6
Time Frame
6 week treatment period
Secondary Outcome Measure Information:
Title
Mean change from baseline in FEV1 at week 6
Time Frame
6 week treatment period
Title
Mean change from baseline in ACT(Asthma Control Test) at week 6
Time Frame
6 week treatment period
Title
Safety assessment(Comparison of the adverse event profiles throughout the course of the study)
Time Frame
6 week treatment period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis or presence of asthma within 3 months of the prestudy visit Increase in PEF ≥ 20% or ≥ 60L/min from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit Increase in FEV1 ≥ 12% and ≥ 200mL from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit FEV1 or PEF between 60% and 85% of the predicted value at screening or within the 3 months of the prestudy visit Having signed an informed consent Exclusion Criteria: Patient who has severe asthma Patient who has any significant medical condition that might compromise patient safety, interfere with evaluation or preclude completion of the study other protocol-defined inclusion/exclusion criteria may apply Patient with an AST or ALT > 2x ULN (upper limit of normal) in the screening visit Patient with more than 10 pack year of cigarettes history
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Young Kyoon Kim, MD
Organizational Affiliation
Seoul ST. Mary's Hospital The Catholic University of Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chonbuk National University Hospital
City
Chonbuk
Country
Korea, Republic of
Facility Name
Chungbuk National University Hospital
City
Chungbuk
Country
Korea, Republic of
Facility Name
Chonnam National University Hospital
City
Gwangju
Country
Korea, Republic of
Facility Name
Ajou University Hospital
City
Gyeonggi
Country
Korea, Republic of
Facility Name
Bucheon St. Mary's Hospital, The Catholic University of Korea
City
Gyeonggi
Country
Korea, Republic of
Facility Name
Hallym University Sacred Heart Hospital
City
Gyeonggi
Country
Korea, Republic of
Facility Name
Soon Chun Hyang University Bucheon Hospital
City
Gyeonggi
Country
Korea, Republic of
Facility Name
Konkuk University Medical Center
City
Seoul
Country
Korea, Republic of
Facility Name
Korea University Guro Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
KyungHee University Medical Center
City
Seoul
Country
Korea, Republic of
Facility Name
Seoul St. Mary's Hospital, The Catholic University of Korea
City
Seoul
Country
Korea, Republic of
Facility Name
Soonchunhyang University Hospital, Seoul
City
Seoul
Country
Korea, Republic of
Facility Name
St. Paul's Hospital, The Catholic University of Korea
City
Seoul
Country
Korea, Republic of
Facility Name
Yonsei University, Gangnam Severance Hospital
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of SA09012 in Asthma

We'll reach out to this number within 24 hrs